Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The user is considering using these alongside Pyrilutamide 0.9%.

New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

User seeks KX-826 anti-androgen product and asks for purchase suggestions and experiences. Dave-8D recommends buying powder from the same website and making a topical solution, mentioning possible high dosage from Minoxidil max causing side effects.

PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

A user is seeking topical versions of minoxidil and finasteride in Australia that do not contain propylene glycol. They are looking for alternatives due to potential irritation from propylene glycol.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The user plans to use RU58841 in the morning and Pyrilutamide in the evening for hair loss treatment, considering replacing Fluridil with Pyrilutamide. They believe Pyrilutamide is effective.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.

Applying Epidermal Growth Factor (EGF) topically may improve skin and potentially promote scalp health and hair growth, especially after microneedling. The user shares their positive experience with EGF and provides a product link.

AltruisticBro's experience with Fluridil (Eucapil) as a hair loss treatment, and the current blood work results associated with it. They are not willing to take finasteride due to potential permanent side effects.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.